CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We lower our 12-month price target by $21 to $63, 13.6x our FY 26 EPS estimate (up $0.02 to $4.62; FY 27 estimate up $0.01 to $5.02). Our target multiple reflects a discount to COO's one-year historical forward average of 17.2x and well below the company's 24.9x forward average over the past five years amid ongoing restructuring efforts and uncertainty about long-term strategy given the ongoing strategic business review. We also note recent tariff headwinds and market disruption from the ongoing U.S./Iran conflict. Nonetheless, we expect near-term sales and margin improvement, with recent U.S. vision business trends appearing supportive and restructuring efforts likely to improve profitability, in our view. We anticipate near 5.6% sales growth in FY 26, above the 5.1% growth seen in FY 25, while we see adjusted operating margin improvement to near 26.7% in FY 26 from 25.8%.